QuidelOrtho (QDEL) Stock Analysis & AI Equity Report

Medical - Specialties USD Explore free reports

QuidelOrtho (QDEL) overview

QuidelOrtho (QDEL) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 2,730m and operating profit of USD -919m; the year-end share price was 29.30 USD and market capitalisation was USD 1,989m. QuidelOrtho is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get QuidelOrtho's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 1,921mFY 2025
Share price29.30 USDFY 2025 year end
RevenueUSD 2,730mFY 2025
Operating profitUSD -919mFY 2025
Net earningsUSD -1,132mFY 2025
Market capitalisationUSD 1,989mFY 2025 year end

About QuidelOrtho

QuidelOrtho develops and sells diagnostic testing products and solutions in immunoassay, molecular testing, clinical chemistry, and transfusion medicine. Its portfolio includes laboratory instruments and tests, point of care and molecular diagnostics, and transfusion medicine products. It sells directly and through distributors for professional and individual use. Customers include hospitals, laboratories, physician offices, clinics, pharmacies, blood banks, and donor centers.

Generate the QuidelOrtho report

QuidelOrtho is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for QuidelOrtho and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on QuidelOrtho

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.